Search

Jazz Pharmaceuticals PLC

Slēgts

SektorsVeselības aprūpe

240 -2.37

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

244.23

Max

247.73

Galvenie mērījumi

By Trading Economics

Ienākumi

-100M

193M

Pārdošana

139M

1.2B

P/E

Sektora vidējais

16.893

56.597

EPS

4.89

Peļņas marža

15.956

Darbinieki

2,890

EBITDA

-126M

418M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+21.21% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

138M

16B

Iepriekšējā atvēršanas cena

242.37

Iepriekšējā slēgšanas cena

240

Ziņu noskaņojums

By Acuity

26%

74%

39 / 339 Rangs Healthcare

Jazz Pharmaceuticals PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. sept. 20:02 UTC

News

UBS raised its price target on Jazz Pharmaceuticals to $337, maintaining a Buy rating amid confidence in growth prospects. Shares are trading higher today.

2026. g. 8. sept. 20:03 UTC

Jazz Pharmaceuticals PLC is declining amid broader pharmaceuticals sector weakness, breaking a recent trend of higher daily closes since Friday.

2026. g. 4. sept. 19:36 UTC

Jazz Pharmaceuticals PLC shares are lower today amid rising Treasury yields and strong labor market data, reflecting broader market trends.

2026. g. 3. sept. 21:21 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, reflecting ongoing pressure despite broader market strength and decreasing rate hike expectations.

2026. g. 2. sept. 19:46 UTC

Jazz Pharmaceuticals PLC shares are higher today, despite an earlier pullback. Broader market conditions include rising U.S. Treasury yields amid inflation concerns.

2026. g. 1. sept. 19:54 UTC

Event
News

Jazz Pharmaceuticals shares are lower despite positive Phase 3 trial results for Ziihera, influenced by tightening monetary policy expectations and rising Treasury yields.

2026. g. 31. aug. 23:41 UTC

Event
News

Jazz Pharmaceuticals PLC reported positive results from the HERIZON-GEA-01 trial for Ziihera, leading shares higher in after-hours trading.

2026. g. 28. aug. 20:02 UTC

Jazz Pharmaceuticals PLC shares are lower today, reversing a trend of higher closes. Broader market pressures include rising U.S. Treasury yields amid inflation concerns.

2026. g. 26. aug. 20:08 UTC

Social Media
News
Event

Jazz Pharmaceuticals PLC shares are lower following a $1 billion note offering and potential $225 million buyback, despite positive FDA approvals and target raises from analysts.

2026. g. 25. aug. 20:07 UTC

News
Social Media

Jazz Pharmaceuticals rises on FDA approval of Ziihera for treating advanced HER2-positive gastroesophageal cancer. Bank of America sets price target at $307.

2026. g. 24. aug. 19:26 UTC

Social Media

Jazz Pharmaceuticals shares are lower amid broader market sentiment influenced by geopolitical tensions. Ziihera's potential in the HER2+ market presents a growth opportunity.

2026. g. 22. aug. 00:02 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline since Friday's close, despite broader gains in major U.S. stocks.

2026. g. 21. aug. 20:06 UTC

Jazz Pharmaceuticals PLC shares are higher during Friday's session, reflecting strong upward momentum since Thursday's close, despite a recent pullback from session highs.

2026. g. 20. aug. 19:56 UTC

Jazz Pharmaceuticals PLC shares are lower amid a broader market decline following disappointing sales growth and guidance from Walmart. They remain below their 20-day moving average.

2026. g. 19. aug. 22:36 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline from regular trading, despite a broader recovery in equities.

2026. g. 18. aug. 20:03 UTC

Jazz Pharmaceuticals shares are trading higher, reflecting strength in the pharmaceuticals sector, despite a slight pullback from earlier session gains.

2026. g. 17. aug. 23:31 UTC

Jazz Pharmaceuticals PLC shares declined during after-market hours, reflecting broader market pressures from rising crude oil prices amid escalating U.S.-Iran tensions.

2026. g. 12. aug. 19:46 UTC

News

Jazz Pharmaceuticals shares are higher after Q2 revenue rose 16% to $1.21 billion, exceeding expectations. The company raised its full-year guidance to $4.68 billion.

2026. g. 11. aug. 22:46 UTC

Jazz Pharmaceuticals PLC shares advanced in after-market trading, diverging from broader market trends that closed lower amid rising crude oil prices.

2026. g. 10. aug. 19:56 UTC

Event
Social Media
News

Jazz Pharmaceuticals PLC to acquire Actio Biosciences for $820 million, enhancing its rare epilepsy portfolio. Shares are higher despite earlier session pullback.

2026. g. 7. aug. 19:36 UTC

Jazz Pharmaceuticals shares are higher today, reflecting broader market gains amid expectations the Federal Reserve may pause interest rate hikes.

2026. g. 6. aug. 19:21 UTC

Jazz Pharmaceuticals PLC shares are lower today, despite earlier gains. Mixed economic signals contribute to cautious sentiment ahead of the non-farm payrolls report.

2026. g. 5. aug. 19:36 UTC

News

Shares of Jazz Pharmaceuticals PLC are lower today, despite earlier gains. The company raised its full-year revenue guidance, driven by strong performance from Xywav.

2026. g. 4. aug. 20:04 UTC

Social Media
News

Jazz Pharmaceuticals PLC shares rise as analysts upgrade price targets, following strong Q2 results that beat revenue estimates and boosted 2026 sales guidance.

2026. g. 3. aug. 23:02 UTC

News

Jazz Pharmaceuticals reported Q2 revenues of $1.208 billion, exceeding expectations. Shares advanced in after-market trading following the raised full-year guidance.

2026. g. 31. jūl. 23:21 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market trading, pulled back from earlier session highs amid broader market declines, particularly in major tech stocks.

2026. g. 30. jūl. 19:59 UTC

Jazz Pharmaceuticals shares are higher, reflecting broader market recovery amid significant gains in the technology sector. The stock is near the upper end of its one-month range.

2026. g. 29. jūl. 18:26 UTC

Jazz Pharmaceuticals PLC is trading higher during Wednesday's session, with fluctuations within a routine range and positioned above its 20-day moving average.

2026. g. 28. jūl. 23:46 UTC

Jazz Pharmaceuticals PLC shares are higher in after-market trading, recovering from an early low and remaining above the 20-day moving average.

2026. g. 27. jūl. 19:37 UTC

Social Media

Jazz Pharmaceuticals PLC is trading higher, recently reaching a new 52-week high amid increased investor interest and significant average volume exceeding $50 million.

Salīdzinājums

Cenas izmaiņa

Jazz Pharmaceuticals PLC Prognoze

Cenas mērķis

By TipRanks

21.21% augšup

Prognoze 12 mēnešiem

Vidējais 297.933 USD  21.21%

Augstākais 337 USD

Zemākais 271 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Jazz Pharmaceuticals PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

16

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

39 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

help-icon Live chat